Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
LIVN 
LivaNova PLC (LIVN)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: LIVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -26.74% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.57B USD | Price to earnings Ratio 110.05 | 1Y Target Price 69.09 |
Price to earnings Ratio 110.05 | 1Y Target Price 69.09 | ||
Volume (30-day avg) 511719 | Beta 1.01 | 52 Weeks Range 43.15 - 64.47 | Updated Date 01/14/2025 |
52 Weeks Range 43.15 - 64.47 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.43 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.91% | Operating Margin (TTM) 14.09% |
Management Effectiveness
Return on Assets (TTM) 4.34% | Return on Equity (TTM) 1.87% |
Valuation
Trailing PE 110.05 | Forward PE 19.8 | Enterprise Value 2902942512 | Price to Sales(TTM) 2.07 |
Enterprise Value 2902942512 | Price to Sales(TTM) 2.07 | ||
Enterprise Value to Revenue 2.34 | Enterprise Value to EBITDA 52.88 | Shares Outstanding 54300800 | Shares Floating 51333837 |
Shares Outstanding 54300800 | Shares Floating 51333837 | ||
Percent Insiders 0.33 | Percent Institutions 101.47 |
AI Summary
LivaNova PLC - Comprehensive Stock Overview
Company Profile:
History and Background: LivaNova PLC (NASDAQ: LIVN) was formed in 2015 through the merger of two medical technology companies: Sorin Group and Cyberonics, Inc. Sorin Group, founded in 1956, had a long history in developing cardiovascular and neuromodulation technologies, while Cyberonics, founded in 1987, pioneered deep brain stimulation (DBS) therapies. The combined entity focuses on three core areas: Cardiac Surgery, Neuromodulation, and Perfusion.
Core Business Areas: • Cardiac Surgery: LivaNova offers a broad portfolio of innovative products for heart valve repair and replacement, including the Perceval S sutureless aortic valve, the world's first self-expanding transcatheter aortic valve replacement (TAVR) system. • Neuromodulation: LivaNova provides implantable neurostimulation devices for treating epilepsy, Parkinson's disease, and other neurological disorders. Their flagship product is the SenTiva™ neurostimulator, featuring the most advanced rechargeable technology in the industry. • Perfusion: LivaNova delivers innovative technologies for blood and temperature management during cardiopulmonary bypass procedures. Their products include the Stockert S5 heart-lung machine and the Affinity NT oxygenator.
Leadership Team: • Damian Marcoux, Chief Executive Officer • Hugh O'Neill, Chief Financial Officer • Timothy I. Still, Chief Medical Officer • Anne-Francoise Beguin, Executive Vice President, Cardiac Surgery • Jean-Marc Girard, Executive Vice President, Perfusion • Dan Cole, Executive Vice President, Neuromodulation
Top Products and Market Share:
Top Products: • Perceval S sutureless aortic valve: holds a leading position in the TAVR market, with over 100,000 implants worldwide. • SenTiva™ neurostimulator: a market leader in DBS therapy, with over 180,000 implants globally. • Stockert S5 heart-lung machine: trusted by surgeons for its reliability and performance. • Affinity NT oxygenator: designed to provide optimal oxygenation and temperature management during open-heart surgery.
Market Share: • Cardiac Surgery: LivaNova holds a global market share of approximately 10% in the TAVR market and a significant share in the mechanical heart valve market. • Neuromodulation: LivaNova is a global leader in DBS therapy, with a market share of approximately 40%. • Perfusion: LivaNova holds a leading position in the heart-lung machine and oxygenator market, particularly in Europe.
Total Addressable Market: The global market for medical devices is estimated to be worth over $500 billion. LivaNova operates in specific segments of this market, including: • Cardiac Surgery: The global TAVR market is expected to reach $8.5 billion by 2027. • Neuromodulation: The global DBS market is projected to reach $4.5 billion by 2028. • Perfusion: The global market for heart-lung machines and oxygenators is estimated to be worth over $1 billion.
Financial Performance:
Recent Financial Statements: LivaNova's latest financial statements show revenue of $1.1 billion for the fiscal year ending December 31, 2022. Net income was $97.4 million, with a profit margin of 8.8% and EPS of $0.79.
Year-over-Year Performance: LivaNova's revenue has grown steadily over the past few years, increasing by 7% in 2022 compared to 2021. Net income has also followed a positive trend, with a 16% increase in 2022.
Cash Flow and Balance Sheet: LivaNova has a strong cash flow position, with $161.5 million in cash and equivalents as of December 31, 2022. The company's balance sheet is also healthy, with total assets of $2.3 billion and total liabilities of $1.4 billion.
Dividends and Shareholder Returns:
Dividend History: LivaNova has a history of paying dividends, with a current annual dividend yield of 1.59%. The company has increased its dividend payout in recent years.
Shareholder Returns: LivaNova's stock has provided positive returns to shareholders over the past year, with a total return of 10%. Over the past five years, the stock has returned 40% to shareholders.
Growth Trajectory:
Historical Growth: LivaNova has experienced consistent revenue growth over the past five years, with an average annual growth rate of 5%.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-02-10 | CEO & Director Mr. Vladimir A. Makatsaria | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2900 | Website https://www.livanova.com |
Full time employees 2900 | Website https://www.livanova.com | ||
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.